Humacyte (HUMA) Other Non-Current Assets (2020 - 2026)
Humacyte (HUMA) reported Other Non-Current Assets of $209000.0 for Q1 2026, down 83.1% year-over-year from $1.2 million in Q1 2025, and down 68.9% quarter-over-quarter from $672000.0 in Q4 2025.
Humacyte (HUMA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Other Non-Current Assets data on file, last reported at $209000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $209000.0, down 83.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $209000.0 (down 83.1% YoY), and the FY2025 annual result was $672000.0, down 46.28% from the prior year.
- Other Non-Current Assets slipped to $209000.0 in Q1 2026 per HUMA's latest filing, from $672000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $50.4 million in Q3 2024 and troughed at $209000.0 in Q4 2023.
- A 5-year average of $4.9 million and a median of $821500.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 5794.74% in 2024, then plunged 99.59% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $682000.0 in 2022, then slumped by 69.35% to $209000.0 in 2023, then surged by 498.56% to $1.3 million in 2024, then slumped by 46.28% to $672000.0 in 2025, then plunged by 68.9% to $209000.0 in 2026.
- Business Quant data shows HUMA's Other Non-Current Assets at $209000.0 in Q1 2026, $672000.0 in Q4 2025, and $209000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | 209,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | 672,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 50.40 Mn |
| Jun 30, 2024 | 815,000.00 |
| Mar 31, 2024 | 828,000.00 |
| Dec 31, 2023 | 209,000.00 |
| Sep 30, 2023 | 855,000.00 |
| Dec 31, 2022 | 682,000.00 |
| Jun 30, 2021 | 15,397.00 |
| Dec 31, 2020 | 28,570.00 |